89 related articles for article (PubMed ID: 32715787)
1. Moxidectin: an oral treatment for human onchocerciasis.
Milton P; Hamley JID; Walker M; Basáñez MG
Expert Rev Anti Infect Ther; 2020 Nov; 18(11):1067-1081. PubMed ID: 32715787
[TBL] [Abstract][Full Text] [Related]
2. Can mass drug administration of moxidectin accelerate onchocerciasis elimination in Africa?
Kura K; Milton P; Hamley JID; Walker M; Bakajika DK; Kanza EM; Opoku NO; Howard H; Nigo MM; Asare S; Olipoh G; Attah SK; Mambandu GL; Kennedy KK; Kataliko K; Mumbere M; Halleux CM; Hopkins A; Kuesel AC; Kinrade S; Basáñez MG
Philos Trans R Soc Lond B Biol Sci; 2023 Oct; 378(1887):20220277. PubMed ID: 37598705
[TBL] [Abstract][Full Text] [Related]
3. An Updated Economic Assessment of Moxidectin Treatment Strategies for Onchocerciasis Elimination.
Turner HC; Kura K; Roth B; Kuesel AC; Kinrade S; Basáñez MG
Clin Infect Dis; 2024 Apr; 78(Supplement_2):S138-S145. PubMed ID: 38662693
[TBL] [Abstract][Full Text] [Related]
4. How Can Onchocerciasis Elimination in Africa Be Accelerated? Modeling the Impact of Increased Ivermectin Treatment Frequency and Complementary Vector Control.
Verver S; Walker M; Kim YE; Fobi G; Tekle AH; Zouré HGM; Wanji S; Boakye DA; Kuesel AC; de Vlas SJ; Boussinesq M; Basáñez MG; Stolk WA
Clin Infect Dis; 2018 Jun; 66(suppl_4):S267-S274. PubMed ID: 29860291
[TBL] [Abstract][Full Text] [Related]
5. Elimination of transmission of onchocerciasis (river blindness) with long-term ivermectin mass drug administration with or without vector control in sub-Saharan Africa: a systematic review and meta-analysis.
Mutono N; Basáñez MG; James A; Stolk WA; Makori A; Kimani TN; Hollingsworth TD; Vasconcelos A; Dixon MA; de Vlas SJ; Thumbi SM
Lancet Glob Health; 2024 May; 12(5):e771-e782. PubMed ID: 38484745
[TBL] [Abstract][Full Text] [Related]
6. Ocular onchocerciasis: current management and future prospects.
Babalola OE
Clin Ophthalmol; 2011; 5():1479-91. PubMed ID: 22069350
[TBL] [Abstract][Full Text] [Related]
7. Alternative treatment strategies to accelerate the elimination of onchocerciasis.
Boussinesq M; Fobi G; Kuesel AC
Int Health; 2018 Mar; 10(suppl_1):i40-i48. PubMed ID: 29471342
[TBL] [Abstract][Full Text] [Related]
8. The World Health Organization 2030 goals for onchocerciasis: Insights and perspectives from mathematical modelling: NTD Modelling Consortium Onchocerciasis Group.
NTD Modelling Consortium Onchocerciasis Group
Gates Open Res; 2019; 3():1545. PubMed ID: 31723729
[TBL] [Abstract][Full Text] [Related]
9. Reaching the last mile: main challenges relating to and recommendations to accelerate onchocerciasis elimination in Africa.
Gebrezgabiher G; Mekonnen Z; Yewhalaw D; Hailu A
Infect Dis Poverty; 2019 Jul; 8(1):60. PubMed ID: 31269966
[TBL] [Abstract][Full Text] [Related]
10. Time series analysis of onchocerciasis data from Mexico: a trend towards elimination.
Lara-Ramírez EE; Rodríguez-Pérez MA; Pérez-Rodríguez MA; Adeleke MA; Orozco-Algarra ME; Arrendondo-Jiménez JI; Guo X
PLoS Negl Trop Dis; 2013; 7(2):e2033. PubMed ID: 23459370
[TBL] [Abstract][Full Text] [Related]
11. The case for vaccine development in the strategy to eradicate river blindness (onchocerciasis) from Africa.
Makepeace BL; Babayan SA; Lustigman S; Taylor DW
Expert Rev Vaccines; 2015; 14(9):1163-5. PubMed ID: 26091691
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of moxidectin against strongyloidiasis.
Luvira V; Watthanakulpanich D
Lancet Infect Dis; 2024 Feb; 24(2):118-119. PubMed ID: 37949091
[No Abstract] [Full Text] [Related]
13. Moxidectin versus ivermectin for strongyloidiasis control.
Gandasegui J; Muñoz J; Fleitas P; Mazzi C; Bisoffi Z
Lancet Infect Dis; 2024 Mar; 24(3):e152. PubMed ID: 38237614
[No Abstract] [Full Text] [Related]
14. Onchocerciasis (river blindness) - more than a century of research and control.
Brattig NW; Cheke RA; Garms R
Acta Trop; 2021 Jun; 218():105677. PubMed ID: 32857984
[TBL] [Abstract][Full Text] [Related]
15. Treatment of onchocerciasis.
Van Laethem Y; Lopes C
Drugs; 1996 Dec; 52(6):861-9. PubMed ID: 8957156
[TBL] [Abstract][Full Text] [Related]
16. Avermectin Derivatives, Pharmacokinetics, Therapeutic and Toxic Dosages, Mechanism of Action, and Their Biological Effects.
El-Saber Batiha G; Alqahtani A; Ilesanmi OB; Saati AA; El-Mleeh A; Hetta HF; Magdy Beshbishy A
Pharmaceuticals (Basel); 2020 Aug; 13(8):. PubMed ID: 32824399
[TBL] [Abstract][Full Text] [Related]
17. Onchocerciasis Elimination: Progress and Challenges.
Lakwo T; Oguttu D; Ukety T; Post R; Bakajika D
Res Rep Trop Med; 2020; 11():81-95. PubMed ID: 33117052
[TBL] [Abstract][Full Text] [Related]
18. Safety of Simparica Trio
Mathur S; Malpas PB; Mahabir S; Boucher J; Pullins A; Gagnon G; McTier TL; Maeder S
Parasit Vectors; 2023 Mar; 16(1):119. PubMed ID: 37004097
[TBL] [Abstract][Full Text] [Related]
19. Ivermectin and moxidectin against soil-transmitted helminth infections.
Hürlimann E; Hofmann D; Keiser J
Trends Parasitol; 2023 Apr; 39(4):272-284. PubMed ID: 36804383
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of oral moxidectin in individuals with Onchocerca volvulus infection.
Tan B; Opoku N; Attah SK; Awadzi K; Kuesel AC; Lazdins-Helds J; Rayner C; Ryg-Cornejo V; Sullivan M; Fleckenstein L
PLoS Negl Trop Dis; 2022 Mar; 16(3):e0010005. PubMed ID: 35333880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
